The company reported a preliminary net profit of RON28.8 million in 2013, up 6.3% on the year.
Overall revenue is seen at RON356.17 million while the total expenses are estimated to reach RON319.29 million.
The number of employees will stay unchanged at 1,465, the company stated.
According to previous data, in 2013, the company reported $26.9 million exports, up 34% on the year, while for 2014, the company estimates a 10% exports hike on the backdrop of expansion.
On the Romanian market, Antibiotice ranks 11th, with a 2.5% share, according to market researcher Cegedim.
Antibiotice is majority-owned by Romania’s Health Ministry, with a 53.02% stake, while investment fund SIF Oltenia (SIF5.RO) holds a 10.32% stake.